PARP1 and osteosarcoma: Consistent with this, one study showed that osteosarcoma cell lines with BRCAness (MG-63, ZK-58, Saos-2, and MNNG-HOS) were sensitive to the PARP1 inhibitor talazoparib, while a cell line with a heterozygous BRCA2 mutation (U2-OS) was not [259].